© 1995 American Heart Association, Inc.
Articles |
Redox Status and Protein Binding of Plasma Homocysteine and Other Aminothiols in Patients With Early-Onset Peripheral Vascular Disease
Homocysteine and Peripheral Vascular Disease
From the Department of Pharmacology and Toxicology (M.A.M., A.M.S., P.M.U.) and the Department of Oncology (P.E.L.), University of Bergen, N-5021 Haukeland Hospital, Bergen, Norway, and the Department of Surgery (C.B.), Karolinska Hospital, S-104 01 Stockholm, Sweden.
Correspondence to Per Magne Ueland, MD, Department of Pharmacology and Toxicology, University of Bergen, N-5021 Haukeland Hospital, Bergen, Norway.
Abstract Elevated total homocysteine (Hcy) in plasma is an independent risk factor for early-onset vascular disease in the coronary, cerebral, and peripheral arteries. Different forms of Hcy, and their relation to other aminothiols in plasma, have not been investigated in patients with vascular disease. We therefore investigated 65 patients (35 men and 30 women) operated on for peripheral arterial disease at <50 years of age and 65 age- and sex-matched control subjects. Total, reduced, oxidized, and protein-bound Hcy, cysteine (Cys), and cysteinylglycine (CysGly) were measured 0 to 11 years (mean, 6 years) postoperatively, in the fasting state, and after a standard methionine loading dose that caused a transient increase in reduced, oxidized, and protein-bound Hcy. All forms of Hcy and Cys, except reduced Cys, were higher in fasting patients than fasting control subjects. A similar difference between the groups was observed after methionine loading. The levels of most Hcy forms both during fasting and after methionine loading were related to smoking, but multivariate analysis showed that the difference between patients and control subjects could not be explained by smoking alone. Notably, reduced Cys and the reduced/total ratio for Cys were significantly higher in control subjects than in patients, both during fasting and after methionine loading. In both groups, the redox status and protein binding of the various aminothiols in plasma were interactive, as demonstrated by positive correlations between their reduced/total ratios and by a decrease in protein-bound Cys when protein-bound Hcy was elevated during methionine loading. Serum folate and to a lesser degree serum cobalamin and vitamin B6 were predictors of oxidized and protein-bound Hcy in some patients and control subject subgroups. Thus, reduced, oxidized, and protein-bound Hcy are elevated and reduced Cys is decreased in patients with peripheral arterial disease. Reduced Hcy acts as a pro-oxidant in vitro and is a possible atherogenic agent, whereas reduced Cys may be a protective agent as a part of the antioxidant defense system. The protein binding and redox status of different plasma aminothiols are interactive in a way suggesting ongoing redox cycling and disulfide exchange reactions. Thus, Hcy is one component in a complex system.
Key Words: risk factor • cysteine • cysteinylglycine • methionine loading • vitamins
This article has been cited by other articles:
 |
|
 |
|
  A. Pinna, C. Carru, A. Zinellu, S. Dore, L. Deiana, and F. Carta Plasma homocysteine and cysteine levels in retinal vein occlusion. Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 4067 - 4071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Refsum, E. Nurk, A. D. Smith, P. M. Ueland, C. G. Gjesdal, I. Bjelland, A. Tverdal, G. S. Tell, O. Nygard, and S. E. Vollset The Hordaland Homocysteine Study: A Community-Based Study of Homocysteine, Its Determinants, and Associations with Disease J. Nutr., June 1, 2006; 136(6): 1731S - 1740S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Samson, Z. Yungst, and D. P. Showalter Homocysteine, a Risk Factor for Carotid Atherosclerosis, Is Not a Risk Factor for Early Recurrent Carotid Stenosis Following Carotid Endarterectomy Vascular and Endovascular Surgery, July 1, 2004; 38(4): 345 - 348. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Lind, B. Hedblad, B. Hultberg, L. Stavenow, L. Janzon, and F. Lindgarde Risk of Myocardial Infarction in Relation to Plasma Levels of Homocysteine and Inflammation-Sensitive Proteins: A Long-Term Nested Case-Control Study Angiology, July 1, 2003; 54(4): 401 - 410. [Abstract] [PDF]
|
|
|
|
 |
|
 L. El-Khairy, S. E. Vollset, H. Refsum, and P. M. Ueland Plasma Total Cysteine, Mortality, and Cardiovascular Disease Hospitalizations: The Hordaland Homocysteine Study Clin. Chem., June 1, 2003; 49(6): 895 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. El-Khairy, S. E Vollset, H. Refsum, and P. M Ueland Plasma total cysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine Study Am. J. Clinical Nutrition, February 1, 2003; 77(2): 467 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. El-Khairy, S. E. Vollset, H. Refsum, and P. M. Ueland Predictors of Change in Plasma Total Cysteine: Longitudinal Findings from the Hordaland Homocysteine Study Clin. Chem., January 1, 2003; 49(1): 113 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. De Bree, W. M. M. Verschuren, D. Kromhout, L. A. J. Kluijtmans, and H. J. Blom Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease Pharmacol. Rev., December 1, 2002; 54(4): 599 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Weiss, C. Keller, U. Hoffmann, and J. Loscalzo Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia Vascular Medicine, August 1, 2002; 7(3): 227 - 239. [Abstract] [PDF]
|
|
|
|
 |
|
 A. K. Majors, S. Sengupta, B. Willard, M. T. Kinter, R. E. Pyeritz, and D. W. Jacobsen Homocysteine Binds to Human Plasma Fibronectin and Inhibits Its Interaction With Fibrin Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1354 - 1359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Makin, S.H. Silverman, and G.Y.H. Lip Peripheral vascular disease and Virchow's triad for thrombogenesis QJM, April 1, 2002; 95(4): 199 - 210. [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Dimitrova, K. W. DeGroot, A. M. Pacquing, J. P. Suyderhoud, E. A. Pirovic, T. J. Munro, J. A. Wieneke, A. K. Myers, and Y. D. Kim Estradiol prevents homocysteine-induced endothelial injury in male rats Cardiovasc Res, February 15, 2002; 53(3): 589 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Nedrebo, O. Nygard, P. M. Ueland, and E. A. Lien Plasma Total Homocysteine in Hyper- and Hypothyroid Patients before and during 12 Months of Treatment Clin. Chem., September 1, 2001; 47(9): 1738 - 1741. [Full Text] [PDF]
|
|
|
|
 |
|
 A. d. Bree, W. M. M. Verschuren, H. J. Blom, and D. Kromhout Lifestyle Factors and Plasma Homocysteine Concentrations in a General Population Sample Am. J. Epidemiol., July 15, 2001; 154(2): 150 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Doshi, I. F. W. McDowell, S. J. Moat, D. Lang, R. G. Newcombe, M. B. Kredan, M. J. Lewis, and J. Goodfellow Folate Improves Endothelial Function in Coronary Artery Disease : An Effect Mediated by Reduction of Intracellular Superoxide? Arterioscler Thromb Vasc Biol, July 1, 2001; 21(7): 1196 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Williams, J. A. Maggiore, R. D. Reynolds, and C. M. Helgason Novel Approach for the Determination of the Redox Status of Homocysteine and Other Aminothiols in Plasma from Healthy Subjects and Patients with Ischemic Stroke Clin. Chem., June 1, 2001; 47(6): 1031 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. El-Khairy, P. M. Ueland, H. Refsum, I. M. Graham, and S. E. Vollset Plasma Total Cysteine as a Risk Factor for Vascular Disease : The European Concerted Action Project Circulation, May 29, 2001; 103(21): 2544 - 2549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Khajuria and D. S. Houston Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis Blood, August 1, 2000; 96(3): 966 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Jacobsen Hyperhomocysteinemia and Oxidative Stress : Time for a Reality Check? Arterioscler Thromb Vasc Biol, May 1, 2000; 20(5): 1182 - 1184. [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Lien, B. G. Nedrebø, J. E. Varhaug, O. Nygård, A. Aakvaag, and P. M. Ueland Plasma Total Homocysteine Levels during Short-Term Iatrogenic Hypothyroidism J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1049 - 1053. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. Mansoor, C. Bergmark, S. J. Haswell, I. F. Savage, P. H. Evans, R. K. Berge, A. M. Svardal, and O. Kristensen Correlation between Plasma Total Homocysteine and Copper in Patients with Peripheral Vascular Disease Clin. Chem., March 1, 2000; 46(3): 385 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. El-Khairy, P. M Ueland, O. Nygard, H. Refsum, and S. E Vollset Lifestyle and cardiovascular disease risk factors as determinants of total cysteine in plasma: the Hordaland Homocysteine Study Am. J. Clinical Nutrition, December 1, 1999; 70(6): 1016 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Malinow, A. G. Bostom, and R. M. Krauss Homocyst(e)ine, Diet, and Cardiovascular Diseases : A Statement for Healthcare Professionals From the Nutrition Committee, American Heart Association Circulation, January 12, 1999; 99(1): 178 - 182. [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Siri, P. Verhoef, and F. J. Kok Vitamins B6, B12, and Folate: Association with Plasma Total Homocysteine and Risk of Coronary Atherosclerosis J. Am. Coll. Nutr., October 1, 1998; 17(5): 435 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Moll, D. Farhadi, A. von Eckardstein, G. Assmann, O. Nygard, H. Refsum, P. M. Ueland, M. Farstad, S. E. Vollset, and J. E. Nordrehaug Plasma Homocysteine Levels and Mortality in Patients with Coronary Artery Disease N. Engl. J. Med., November 27, 1997; 337(22): 1631 - 1633. [Full Text]
|
|
|
|
 |
|
 M. H. Moghadasian, B. M. McManus, and J. J. Frohlich Homocyst(e)ine and Coronary Artery Disease: Clinical Evidence and Genetic and Metabolic Background Arch Intern Med, November 10, 1997; 157(20): 2299 - 2308. [Abstract] [PDF]
|
|
|
|
|
|
C. Bergmark, M. A. Mansoor, A. Svardal, and U. d. Faire Redox Status of Plasma Homocysteine and Related Aminothiols in Smoking and Nonsmoking Young Adults, Clin. Chem., October 1, 1997; 43(10): 1997 - 1999. [Full Text]
|
|
|
|
|
|
P. Verhoef, F. J. Kok, D. A.C.M. Kruyssen, E. G. Schouten, J. C.M. Witteman, D. E. Grobbee, P. M. Ueland, and H. Refsum Plasma Total Homocysteine, B Vitamins, and Risk of Coronary Atherosclerosis Arterioscler Thromb Vasc Biol, May 1, 1997; 17(5): 989 - 995. [Abstract] [Full Text]
|
|
|
|
 |
|
 O. Nygard, S. E. Vollset, H. Refsum, I. Stensvold, A. Tverdal, J. E. Nordrehaug, P. M. Ueland, and G. Kvale Total Plasma Homocysteine and Cardiovascular Risk Profile: The Hordaland Homocysteine Study JAMA, November 15, 1995; 274(19): 1526 - 1533. [Abstract] [PDF]
|
|
|
|
|
|
P. N. Hopkins, L. L. Wu, J. Wu, S. C. Hunt, B. C. James, G. M. Vincent, and R. R. Williams Higher Plasma Homocyst(e)ine and Increased Susceptibility to Adverse Effects of Low Folate in Early Familial Coronary Artery Disease Arterioscler Thromb Vasc Biol, September 1, 1995; 15(9): 1314 - 1320. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Sengupta, H. Chen, T. Togawa, P. M. DiBello, A. K. Majors, B. Budy, M. E. Ketterer, and D. W. Jacobsen Albumin Thiolate Anion Is an Intermediate in the Formation of Albumin-S-S-Homocysteine J. Biol. Chem., August 3, 2001; 276(32): 30111 - 30117. [Abstract] [Full Text] [PDF]
|
|